Paper
0
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Authors
Published
Jun 11, 2019
Show more
Save
Tip0
TipSave
Abstract
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.